Literature DB >> 2582432

Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells.

M P Gosland1, B L Lum, B I Sikic.   

Abstract

The cephalosporins are a family of semisynthetic antibiotics, some of which have structural features associated with substrates for the multidrug transporter, P-glycoprotein. The activity of a series of six cephalosporins in reversing multidrug resistance (MDR) was examined in MDR variants (Dx5 cells) of the human sarcoma line MES-SA. Dx5 cells express high levels of the mdr1 gene product P-glycoprotein and are 25- to 30-fold resistant to doxorubicin (DOX), etoposide (VP-16), and vinblastine (VBL). Cytotoxicity was measured by the MTT assay. Cefoperazone (1.0 mM) was the most effective modulator of MDR, lowering the IC50 for VP-16 by 29-fold (29x), for VBL by 16x, and for DOX by 14x. Ceftriaxone at 1.0 mM produced 10x modulation of VP-16 cytotoxicity, 8x for DOX, and 2x for VBL. The reversal of resistance was concentration dependent, decreasing to 4x and 5x, respectively, for DOX with 0.25 mM cefoperazone and ceftriaxone. No modulation of cytotoxicity was observed in the parental MES-SA cells, which do not express mdr1. Cefazolin, cefotetan, cephradine, and ceftazidime were ineffective, producing less than 5x modulation of DOX at 1.0 mM. Among these cephalosporins, cefoperazone and ceftriaxone were the most highly protein bound in the media (30 and 52%), and the most lipid soluble, with octanol/water partitioning coefficients of -0.49 and -0.60. Varying the serum concentration in medium from 5 to 50% had less than a two-fold effect on the modulation of MDR by ceftriaxone. The ability to reverse MDR among these agents is associated with lipid solubility, high protein binding, a polycyclic planar geometry, and the presence of the piperazine group in cefoperazone. These data and the potential for achieving high tissue concentrations indicate that cefoperazone merits further study as a modulator of MDR.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2582432

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

2.  Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs.

Authors:  A Cavalier; D Levêque; J D Peter; J Salmon; H Elkhaïli; Y Salmon; P Nobelis; J Geisert; H Monteil; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Spontaneous multidrug transport in human glioma cells is regulated by transforming growth factors type beta.

Authors:  H J Schluesener; R Meyermann
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

4.  Activation of human peripheral blood T cells does not lead to increased P-glycoprotein expression.

Authors:  X Y Mu; M P Gosland; M M Bartik; J Schimmelpfennig; N E Kay
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

5.  Reversal of multidrug resistance by phenothiazines and structurally related compounds.

Authors:  A Ramu; N Ramu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 6.  ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis.

Authors:  Michael Jablonski; David S Miller; Piera Pasinelli; Davide Trotti
Journal:  Brain Res       Date:  2014-08-28       Impact factor: 3.252

7.  Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20'-vinblastine congeners that lack antimicrotubule activity.

Authors:  L S Borman; W G Bornmann; M E Kuehne
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.

Authors:  T Licht; I Pastan; M Gottesman; F Herrmann
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

Review 9.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 10.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.